...
首页> 外文期刊>Cardiovascular Diabetology >Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8?years follow up study
【24h】

Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8?years follow up study

机译:中度他汀类药物疗法在2型糖尿病合并肾病患者的一级心血管预防中似乎无效。多中心前瞻性8年随访研究

获取原文

摘要

Background Although numerous studies and metanalysis have shown the beneficial effect of statin therapy in CVD secondary prevention, there is still controversy such the use of statins for primary CVD prevention in patients with DM. The purpose of this study was to evaluate the occurrence of total major adverse cardio-vascular events (MACE) in a cohort of patients with type 2 diabetes complicated by nephropathy treated with statins, in order to verify real life effect of statin on CVD primary prevention. Methods We conducted an observational prospective multicenter study on 564 patients with type 2 diabetic nephropathy free of cardiovascular disease attending 21 national outpatient diabetes clinics and followed them up for 8?years. 169 of them were treated with statins (group A) while 395 were not on statins (group B). Results Notably, none of the patients was treated with a high-intensity statin therapy according to last ADA position statement. Total MACE occurred in 32 patients from group A and in 68 patients from group B. Fatal MACE occurred in 13 patients from group A and in 30 from group B; nonfatal MACE occurred in 19 patients from group A and in 38 patients from group B. The analysis of the Kaplan–Meier survival curves showed a not statistically significant difference in the incidence of total (p 0.758), fatal (p 0.474) and nonfatal (p 0.812) MACE between the two groups. HbA1c only showed a significant difference in the incidence of MACE between the two groups (HR 1.201, CI 1.041–1.387, p 0.012). Conclusions These findings suggest that, in a real clinical setting, moderate-intensity statin treatment is ineffective in cardiovascular primary prevention for patients with diabetic nephropathy. Trial registration ClinicalTrials.gov Identifier NCT00535925. Date of registration: September 24, 2007, retrospectively registered
机译:背景技术尽管许多研究和荟萃分析已表明他汀类药物疗法在CVD二级预防中的有益作用,但仍存在争议,例如将他汀类药物用于DM患者的一级CVD预防。这项研究的目的是评估在他汀类药物治疗的2型糖尿病并发肾病患者中总主要不良心血管事件(MACE)的发生,以验证他汀类药物对CVD一级预防的现实作用。方法我们在21家全国门诊糖尿病门诊对564例无心血管疾病的2型糖尿病肾病患者进行了一项观察性前瞻性多中心研究,随访了8年。其中169例接受他汀类药物治疗(A组),而395例未使用他汀类药物治疗(B组)。结果值得注意的是,根据最近的ADA立场声明,没有患者接受高强度他汀类药物治疗。总的MACE发生在A组的32例患者和B组的68例患者中。致命MACE发生在A组的13例患者和B组的30例中; A组的19例患者和B组的38例患者发生了非致命性MACE。对Kaplan–Meier生存曲线的分析显示,总发生率(p 0.758),致命性(p 0.474)和非致命性(p。74)的发生率无统计学意义。 p 0.812)两组之间的MACE。两组之间HbA1c仅显示出MACE的显着差异(HR 1.201,CI 1.041–1.387,P 0.012)。结论这些发现表明,在真实的临床环境中,中等强度的他汀类药物治疗对糖尿病性肾病患者的心血管一级预防无效。试用注册ClinicalTrials.gov标识符NCT00535925。注册日期:2007年9月24日,追溯注册

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号